Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute
This is a single-arm, open-label, dose-escalation study to explore the safety, efficacy, and cytodynamic characteristics of the drug, and to initially observe the efficacy of the drug in subjects with relapsed/refractory B7-H3-positive acute myeloid cell line leukemia.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | December 27, 2024 |
Est. primary completion date | December 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - (1) Age= 18 years old, gender is not limited; - (2) expected survival time= 3 months; - (3) ECOG score 0-1 points; - (4) Acute myeloid leukemia was clearly diagnosed during screening, and tumor cells were positive for B7-H3 expression; - (5) Subjects with relapsed/refractory acute myeloid leukemia who have failed standard treatment or lack effective treatment methods. - (6) Coagulation function, liver and kidney function, cardiopulmonary function meet requirements. - (7) Be able to understand the trial and have signed the informed consent form. Exclusion Criteria: - (1) Malignant tumors other than acute myeloid leukemia within 5 years before screening; - (2) Those who test positive for virus and syphilis; - (3) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification= grade III), severe arrhythmia; - (4) Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment; - (5) Active infection or uncontrollable infection requiring systemic treatment within 7 days prior to screening; - (6) pregnant or lactating women, female subjects who planned to become pregnant within 2 years after cell reinfusion or male subjects whose partners planned to become pregnant within 2 years after their cell reinfusion; - (7) Subjects who were receiving systemic steroid therapy within 7 days prior to the year or who were judged by the investigator to require long-term systemic steroid therapy during treatment (other than inhalation or topical use); - (8) Have participated in other clinical studies within 1 month before screening; - (9) There was evidence of central nervous system invasion during subject screening, such as tumor cells detected in cerebrospinal fluid or imaging showing central infiltration; - (10) Those who have graft-versus-host response and need to use immunosuppressants; - (11) Those with a history of epilepsy or other central nervous system diseases; - (12) Patients with primary immunodeficiency diseases; - (13) situations that other investigators consider unsuitable for enrollment. |
Country | Name | City | State |
---|---|---|---|
China | PersonGen Anke Cellular Therapeutice Co., Ltd. | Hefei | Anhui |
Lead Sponsor | Collaborator |
---|---|
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the safety after UTAA06 injection treatment (Safety) | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. | About 2 years | |
Secondary | To evaluate anti-tumor activity (overall survival) | Defined as the time from start of UTAA06 UTAA06 infusion therapy to death (due to any cause) | About 2 years | |
Secondary | To evaluate anti-tumor activity (duration of response) | Defined as the time from the first tumor assessment of CR or PR, CR or CRi to the first assessment of disease recurrence or progression or death (due to any cause). | About 2 years | |
Secondary | To evaluate anti-tumor activity (progression free survival) | Defined as the time from the start of UTAA06 infusion therapy to the first disease progression or recurrence or death from any cause. | About 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05731219 -
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05061147 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05548088 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Terminated |
NCT03504410 -
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
|
Phase 3 | |
Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
Withdrawn |
NCT03904069 -
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
|
Phase 1 | |
Completed |
NCT05518357 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT03190278 -
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Completed |
NCT02665143 -
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT03886831 -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT03318016 -
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT06084819 -
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 2 | |
No longer available |
NCT05627466 -
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|